AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17223112 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (across dose range)
Number of subjects: 154
Study 17223112 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 154
Study 15470853 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic therapy (systematic mechanical rotation of patients with 40 degree turns)
Number of subjects: 234
Study 15470853 — intervention group
Group type: COMPARATOR
Intervention: Standard turning (turning patients every 2 hours)
Number of subjects: 234
Study 14601817 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextually Relevant (CR) group practicing tying a necktie knot onto a mannequin
Number of subjects: 56
Study 14601817 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Contextually Relevant (NCR) group practicing tying a knot with a rope onto a wooden pole
Number of subjects: 56
Study 14601817 — intervention group
Group type: COMPARATOR
Intervention: Control group that did not practice at all during the acquisition phase
Number of subjects: 56
Study 9676143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented formulas
Number of subjects: 0
Study 7915703 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term prazosin (2 mg orally)
Number of subjects: 12
Study 7915703 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term prazosin (5 mg/12 hr for 3 months)
Number of subjects: 12
Study 7915703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2642866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 13
Study 2642866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 769595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0-3 mg given prior to surgery
Number of subjects: 78
Study 769595 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0-1 mg/kg
Number of subjects: 78
Study 769595 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0-6 mg intramuscularly followed by controlled ventilation
Number of subjects: 78
Study 31036927 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA-CVVH
Number of subjects: 56
Study 31036927 — intervention group
Group type: COMPARATOR
Intervention: NA-CVVH
Number of subjects: 56
Study 28926521 — intervention group
Group type: EXPERIMENTAL
Intervention: TNT009 (7 consecutive cohorts, 0.3-100 mg/kg single doses)
Number of subjects: 64
Study 28926521 — intervention group
Group type: EXPERIMENTAL
Intervention: TNT009 (2 consecutive cohorts, 30 and 60 mg/kg per infusion, 4 weekly infusions)
Number of subjects: 64
Study 28926521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28926521 — intervention group
Group type: EXPERIMENTAL
Intervention: TNT009
Number of subjects: 64
Study 25800582 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary angiography (CAG) performed on admission or within the first 6 hours after arrest; 252 patients (46%) received early CAG.
Number of subjects: 544
Study 25800582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early CAG); 292 patients (54%) did not receive early CAG.
Number of subjects: 544
Study 25800582 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary angiography (CAG)
Number of subjects: 544
Study 24215780 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine (1mg/kg IV bolus followed by 0.69 mg/kg/h IV CRI for 2h)
Number of subjects: 7
Study 24215780 — intervention group
Group type: EXPERIMENTAL
Intervention: Romifidine (80 μg/kg IV bolus followed by 30 μg/kg/h IV CRI for 2h)
Number of subjects: 7
Study 20698793 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard exercise plus Wii bowling (Wii)
Number of subjects: 34
Study 20698793 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise (SG)
Number of subjects: 34
Study 19826293 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat Training with Vibration (SQTV)
Number of subjects: 30
Study 19826293 — intervention group
Group type: COMPARATOR
Intervention: Squat Training without Vibration (SQT)
Number of subjects: 30
Study 19826293 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 17106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I; Perindopril 4 mg/d)
Number of subjects: 0
Study 17106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with interferon (IFN; 3 MU/L; 3 times a week) and ACE-I
Number of subjects: 0
Study 17106926 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) alone
Number of subjects: 0
Study 17106926 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACE-I alone)
Number of subjects: 0
Study 17106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with ACE-I and IFN
Number of subjects: 0
Study 15619490 — intervention group
Group type: EXPERIMENTAL
Intervention: Valved port (PASV; Boston Scientific)
Number of subjects: 73
Study 15619490 — intervention group
Group type: COMPARATOR
Intervention: Nonvalved port (BardPort; Bard Access Systems)
Number of subjects: 73
Study 11379810 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP-extrafine (400 microg daily)
Number of subjects: 172
Study 11379810 — intervention group
Group type: COMPARATOR
Intervention: FP (400 microg daily)
Number of subjects: 172
Study 9223063 — intervention group
Group type: EXPERIMENTAL
Intervention: THA 50 mg
Number of subjects: 28
Study 9223063 — intervention group
Group type: COMPARATOR
Intervention: THA 25 mg
Number of subjects: 28
Study 9223063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 7955168 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole candy 100 mg (single dose)
Number of subjects: 456
Study 7955168 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 150 mg qd for two days
Number of subjects: 456
Study 7955168 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 200 mg qd for two days
Number of subjects: 456
Study 3584957 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention (eight sessions of instruction and practice)
Number of subjects: 0
Study 3584957 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention mentioned)
Number of subjects: 0
Study 29895234 — intervention group
Group type: EXPERIMENTAL
Intervention: Running schedule focusing on running intensity (S-I)
Number of subjects: 447
Study 29895234 — intervention group
Group type: EXPERIMENTAL
Intervention: Running schedule focusing on running volume (S-V)
Number of subjects: 447
Study 28962608 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of home-based exercise (individualised endurance and resistance exercise program and behaviour change coaching) and nurse-delivered symptom self-management intervention
Number of subjects: 92
Study 28962608 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 28962608 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of home-based exercise
Number of subjects: 92
Study 24418865 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment combined with 1% olopatadine ophthalmic solution
Number of subjects: 21
Study 24418865 — intervention group
Group type: COMPARATOR
Intervention: 0.03% tacrolimus ointment combined with placebo eye drops
Number of subjects: 21
Study 23609838 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri NCIMB 30242
Number of subjects: 127
Study 23609838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 21039763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical products with active substances classified by BCS
Number of subjects: 124
Study 21039763 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 active substances
Number of subjects: 124
Study 21039763 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 active substances
Number of subjects: 124
Study 21039763 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 active substances
Number of subjects: 124
Study 21039763 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 4 active substances
Number of subjects: 124
Study 21039763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical products with intra-subject variability higher than predicted
Number of subjects: 124
Study 21039763 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparisons between pharmaceutical products from the four BCS classes
Number of subjects: 124
Study 18158176 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI)
Number of subjects: 97
Study 18158176 — intervention group
Group type: COMPARATOR
Intervention: Milk-free diet (Control group B)
Number of subjects: 97
Study 17060064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine (felodipine)
Number of subjects: 211
Study 17060064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 211
Study 17060064 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril)
Number of subjects: 211
Study 17060064 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin blocker (valsartan)
Number of subjects: 211
Study 17060064 — intervention group
Group type: COMPARATOR
Intervention: Control group (diltiazem monotherapy)
Number of subjects: 211
Study 12660448 — intervention group
Group type: EXPERIMENTAL
Intervention: Münster clamp technique
Number of subjects: 30
Study 12660448 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 30
Study 10936118 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg) every 12 h in addition to standard therapy
Number of subjects: 43
Study 10936118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two puffs every 12 h) in addition to standard therapy
Number of subjects: 43
Study 8813296 — intervention group
Group type: EXPERIMENTAL
Intervention: fast fluid‐attenuated inversion recovery (fast‐FLAIR)
Number of subjects: 7
Study 8813296 — intervention group
Group type: COMPARATOR
Intervention: conventional spin-echo (CSE)
Number of subjects: 7
Study 7827745 — intervention group
Group type: EXPERIMENTAL
Intervention: ordinary head pillow
Number of subjects: 40
Study 7827745 — intervention group
Group type: EXPERIMENTAL
Intervention: heel protectors based on siliconized hollow fibers
Number of subjects: 40
Study 3137488 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (selegiline) for 2 weeks
Number of subjects: 16
Study 3137488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30115037 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher incentive (1 € coffee voucher)
Number of subjects: 472
Study 30115037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no voucher)
Number of subjects: 472
Study 30115037 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 472
Study 30115037 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk ratio
Number of subjects: 472
Study 27917460 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 180
Study 26646534 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrokinematic approach-Hakata method (AKA-H)
Number of subjects: 186
Study 26646534 — intervention group
Group type: COMPARATOR
Intervention: Sham technique (S)
Number of subjects: 186
Study 24012586 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill (TM) training
Number of subjects: 28
Study 24012586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 24012586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 21711512 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Myofascial Trigger Points (MTrPs)
Number of subjects: 72
Study 21711512 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent Myofascial Trigger Points (MTrPs)
Number of subjects: 72
Study 21711512 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH score correlation
Number of subjects: 72
Study 18590407 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs in addition to opioid analgesics
Number of subjects: 789
Study 18590407 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesics alone
Number of subjects: 789
Study 17136232 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of 0.5% lidocaine plus 20 mg propofol (Group P)
Number of subjects: 26
Study 17136232 — intervention group
Group type: COMPARATOR
Intervention: 40 ml of 0.5% lidocaine (Group C)
Number of subjects: 26
Study 12824959 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc powder
Number of subjects: 33
Study 12824959 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 33
Study 10682869 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 0
Study 10682869 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0
Study 10682869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 10682869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplements
Number of subjects: 0
Study 10682869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 0
Study 10682869 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil
Number of subjects: 0
Study 10682869 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal products
Number of subjects: 0
Study 7595746 — intervention group
Group type: EXPERIMENTAL
Intervention: Etopophos (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Number of subjects: 49
Study 7595746 — intervention group
Group type: COMPARATOR
Intervention: VePesid (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Number of subjects: 49
Study 7595746 — intervention group
Group type: EXPERIMENTAL
Intervention: Etopophos and VePesid
Number of subjects: 49
Study 2275328 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.04 mg.kg‐1)
Number of subjects: 40
Study 2275328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7001862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (non-selective beta-blocker)
Number of subjects: 10
Study 7001862 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (cardioselective beta 1-blocker)
Number of subjects: 10
Study 7001862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 10
Study 7001862 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 10
Study 30797401 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to expedited Medicaid enrollment
Number of subjects: 3086
Study 30797401 — intervention group
Group type: COMPARATOR
Intervention: No referral to expedited Medicaid enrollment
Number of subjects: 3086
Study 28158932 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal morbidity (NNM)
Number of subjects: 402
Study 28158932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral ultrasound abnormalities
Number of subjects: 402
Study 28158932 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group allocation
Number of subjects: 402
Study 28158932 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight ratio
Number of subjects: 402
Study 28158932 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant sex
Number of subjects: 402
Study 28158932 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar score
Number of subjects: 402
Study 26009829 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC)
Number of subjects: 269
Study 26009829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 269
Study 26009829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir
Number of subjects: 269
Study 26009829 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 269
Study 22957993 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 123
Study 22957993 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 21846551 — intervention group
Group type: EXPERIMENTAL
Intervention: TF rotary system
Number of subjects: 40
Study 21846551 — intervention group
Group type: COMPARATOR
Intervention: K3 rotary system
Number of subjects: 40
Study 19308727 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 252
Study 19308727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 17259500 — intervention group
Group type: EXPERIMENTAL
Intervention: Boric acid vaginal suppositories (600 mg/day for 14 days)
Number of subjects: 112
Study 17259500 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole (150 mg single dose)
Number of subjects: 112
Study 17259500 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mycological cure irrespective of Candida species
Number of subjects: 112
Study 17259500 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequencies of yeast on direct microscopy
Number of subjects: 112
Study 17259500 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptoms and signs of VVC on the 15th day of treatment
Number of subjects: 112
Study 15212357 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser radiation (655 nm)
Number of subjects: 40
Study 15212357 — intervention group
Group type: COMPARATOR
Intervention: Explorer
Number of subjects: 40
Study 11520725 — intervention group
Group type: COMPARATOR
Intervention: Nasal oxygen (2 L/min)
Number of subjects: 14
Study 11520725 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) (mean 9.25 cm H(2)O)
Number of subjects: 14
Study 11520725 — intervention group
Group type: COMPARATOR
Intervention: Bilevel (mean 13.5/5.2 cm H(2)O)
Number of subjects: 14
Study 11520725 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) (mean pressure 7 to 9 cm H(2)O)
Number of subjects: 14
Study 9663810 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg
Number of subjects: 12
Study 9663810 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg
Number of subjects: 12
Study 9663810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7823668 — intervention group
Group type: EXPERIMENTAL
Intervention: Two blocks of additional intensification therapy
Number of subjects: 1612
Study 7823668 — intervention group
Group type: COMPARATOR
Intervention: One block of intensification therapy at 5 weeks
Number of subjects: 1612
Study 7823668 — intervention group
Group type: COMPARATOR
Intervention: One block of intensification therapy at 20 weeks
Number of subjects: 1612
Study 7823668 — intervention group
Group type: COMPARATOR
Intervention: No intensification therapy
Number of subjects: 1612
Study 2688033 — intervention group
Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy (ASI) with an autologous tumor cell‐BCG vaccine
Number of subjects: 74
Study 2688033 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection plus ASI
Number of subjects: 74
Study 2688033 — intervention group
Group type: COMPARATOR
Intervention: Resection alone (control)
Number of subjects: 74
Study 803910 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional plus vasopressin therapy
Number of subjects: 60
Study 803910 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 60
Study 31825647 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, low-burden, and stepped invitation strategy
Number of subjects: 2012
Study 31825647 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard invitation materials
Number of subjects: 2012
Study 31825647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2012
Study 31825647 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2012
Study 31825647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2012
Study 31207009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intrauterine balloon dilatation therapy at 2 weeks and 6 weeks after surgery
Number of subjects: 200
Study 31207009 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 200
Study 31207009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intrauterine balloon dilatation therapy
Number of subjects: 200
Study 28416171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells
Number of subjects: 28
Study 25661990 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from marijuana
Number of subjects: 0
Study 25661990 — intervention group
Group type: COMPARATOR
Intervention: Continued marijuana use
Number of subjects: 0
Study 23933032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule of Alfuzosin hydrochloride 10mg extended release and Solifenacin succinate 5mg
Number of subjects: 0
Study 23933032 — intervention group
Group type: COMPARATOR
Intervention: Individually administered Xatral XL 10mg tablets (Alfuzosin) and Vesicare 5mg tablets (Solifenacin)
Number of subjects: 0
Study 22202235 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 8
Study 22202235 — intervention group
Group type: COMPARATOR
Intervention: S-1/PSK
Number of subjects: 8
Study 19089501 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational support from physicians
Number of subjects: 246
Study 19089501 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support from physicians
Number of subjects: 246
Study 19089501 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making support from physicians
Number of subjects: 246
Study 19089501 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational support at 2 months
Number of subjects: 246
Study 19089501 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational and emotional support at 2 months
Number of subjects: 246
Study 19089501 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support at 5 months
Number of subjects: 246
Study 16752179 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 1
Number of subjects: 10
Study 16752179 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 2
Number of subjects: 10
Study 15182985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligacast
Number of subjects: 14
Study 15182985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynastab
Number of subjects: 14